ERBB2 and neoplasm: We observed that recurrences were most frequent among women with triple-negative tumours (7.9%), followed by women with ER/PR-positive/HER2-negative tumours (4.5%), and were least frequent among women suffering from HER2-positive tumours (2.7%).